Robroy non-metallic enclosures are used in a variety of outdoor temporary power products, which include both power distribution and control applications. Many of these temporary power applications are life-critical. With the recent necessity for COVID-19 makeshift hospitals globally, temporary power products have seen a significant surge. Fiberglass, polycarbonate, and PVC enclosures from Stahlin and AttaBox are ideal because they are durable, reliable, lightweight, easy to modify and offer precise environmental performance requirements.

Particular applications include portable load banks, generator maintenance panels, portable generator paralleling panels, power distribution carts, portable disconnect panels, generator connect tap boxes, portable transformers, temp-power centers, RV gang boxes, generator controllers, docking stations and various types of power distribution equipment.

As an essential manufacturer for these critical applications, Robroy Enclosures remains open to serve.

Robroy Enclosures offers the most extensive selection of non-metallic enclosures available for meeting the needs of diverse industries, interior and exterior applications, appealing aesthetics, and physical property performance standards, including NEMA 4X and NEMA 6P integrity.

No matter how careful we are, roads and highways are still very risky places to be. They are full of vehicles and commuters; each have their own agenda and sensibilities. Yes, there are traffic rules, but there are also those who are willing to break them to get to their destination sooner and mistakes happen all the time.

Sometimes, this desire to get ahead results in very unfortunate crashes where other drivers or even pedestrians are injured. Those who suffer from injuries must initially not think of anything else other than their own recovery and safety.

In this article, we outline the three things that every car crash victim must bear in mind as they recover from their injuries.

Get all the treatments that you need only from a licensed medical professional

Many states have at-fault policies where those who caused or have the greater responsibility over the crash are made to pay the recovery expenses of those who are injured. However, getting the money might involve a detail-oriented battle with insurers. For this, you will surely need the help of a competent personal injury lawyer such as those from seattlemalpracticelawyers.com.

To make the process a lot easier for you, it is advised that you get treatment only from a licensed medical professional. If you can, refuse to be moved from the crash site until medical help arrives. Don’t worry, this is standard protocol, as you may have unseen injuries that are aggravated by abrupt or misguided movements.

Get all the tests that you can get your hands on

Depending on its severity, a crash can injure you in more ways than you are aware of. Besides telling your attending physician everything that you feel, it’s important that you subject yourself to a general checkup in order to uncover unnoticed physical irregularities. Only after a thorough examination is done should you start believing any declaration that you are fine. Remember, some injuries become a lot more serious simply because they weren’t detected early on.

Aside from taking care of your physical health, you should pay attention to your mental health as well. An accident or car crash is a traumatic experience that can give you anxiety. Seek the help of a mental health professional and heed their advice as to what treatment or therapy you should get.

Never attempt to self-medicate

When you are sent home to recover fully, it’s important that you follow the instructions of your attending physician. Do as told and take only the medications in the doses that have been prescribed to you at the right time. To avoid counterfeits, get the products only from accredited pharmacies. You can ask your doctor for recommendations.
Never attempt to self medicate or even replace the meds prescribed with cheaper alternatives. There might be differences in dosage and substance composition, and these might delay your recovery.

Getting involved in an accident is really unfortunate, especially if it’s caused by the negligence of others. If you are injured, it is important that you follow the advice of the medical professional who assisted you to avoid complications.

111, Inc., a leading integrated online and offline healthcare platform in China, announced that it is launching a new diabetes patient management platform in cooperation with Lilly China.

The two companies will work together to build a comprehensive diabetes patient management platform that includes services such as disease management, disease education and patient support programs to enrich patients’ knowledge of chronic disease management and to better help diabetic patients to self-manage from home. The platform will seek to harness the power of internet hospital technologies, big data and artificial intelligence technologies to provide diabetic patients with a comprehensive digital health management solution.

111 has accumulated extensive experience in operations management in the area of chronic disease, especially in diabetes, laying a solid foundation for the development of the diabetes management platform. With the transformative power of technology, the platform will seek to provide patients with a one-stop solution for “physician consultation + medication” services, allowing patients to consult with qualified physicians online, and receive personalized healthcare management services, online refill service, and medication delivery services.

As the first multinational pharmaceutical company to join the platform, Lilly China will leverage its expertise in the field of diabetes management and will also offer a variety of patient management and support programs, including “Lilly Connected Care Program” and Patient Benefit Program, to eligible diabetes patients, with the aim of providing personalized disease education and health management services. In addition, with its deep experience in the diabetes field, Lilly China will help to develop a directory of disease education resources to help patients understand risk factors, signs and symptoms, and treatment options.

Commenting on Lilly’s collaboration with 111, President and General Manager of Lilly China, Mr. Julio Gay-Ger, said, “The internet + healthcare model has increasingly gained recognition from the Chinese government, and Lilly China is actively exploring innovative business models in collaboration with a number of third-party platforms, including internet hospitals. Joining 111’s diabetes patient platform is an opportunity for Lilly China to conduct disease management and education through online hospitals, and also improve access to Lilly China’s various patient support and benefit programs for diabetic patients.”

“China has over 100 million diabetic patients, and it is crucial to help this large group of patients to manage their health effectively,” said Dr. Yu Gang, Co-Founder and Executive Chairman of 111. “As a technology enabler of the pharmaceutical health ecosystem, 111 looks forward to working with Lilly China to leverage resources and core competence in each of our respective fields, and explore an efficient management model of diabetes. This collaboration aims to deliver better care and medical outcomes for patients with chronic diseases by developing an integrated digital health management platform. Our ambition is to leverage on technology to overcome the constraints of time and location to provide greater convenience for both patients and physicians,” Dr. Yu Gang noted. “Through our platform, we hope to provide patients with better access to information on diet, exercise, and medication specifically tailored to their individual needs, as well as a personalized management and treatment program that could help improve their own health. A step closer to the goals of Healthy China 2030.”

About 111, Inc.

111, Inc. is a leading integrated online and offline healthcare platform in China. The Company provides hundreds of millions of consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy and indirectly through its offline pharmacy network. 111 also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation and electronic prescription services. In addition to providing direct services to consumers through its online retail pharmacy, 111 also enables offline pharmacies to better serve their customers. The Company’s online wholesale pharmacy, 1 Drug Mall, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. The Company’s new retail platform, by integrating the front and back ends of the pharmaceutical supply chain, has formed a smart supply chain, which transforms the flow of pharmaceutical products to pharmacies and modernizes how they serve their customers.

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, announced the launch of its next-generation OMNI® Surgical System for microinvasive glaucoma surgery (MIGS) procedures.

The OMNI Surgical System combines two distinct angle procedures – ab interno trabeculotomy and transluminal viscoelastic delivery. It is the only MIGS device that allows surgeons to target all three points of aqueous humor outflow resistance – trabecular meshwork, Schlemm’s canal and distal collector channels.

“We designed the next generation of our OMNI Surgical System to provide improved ergonomics, intuitive use and smooth microcatheter deployment and retraction, while continuing to deliver excellent outcomes as a standalone treatment, or as a procedure performed in conjunction with cataract surgery,” said Sight Sciences Chief Commercial Officer, Shawn O’Neil. “We’re excited to announce the availability of this improved system, which incorporates many changes based on feedback from our physician customers.”

The upgraded system features several updates designed to enhance its ergonomics and usability including:

An updated Luer lock fitting and pull pin to provide increased efficiency in the priming and preparation of the device,
An ergonomic handle and flexi-grip surface, which fits comfortably and provides stability in the surgeon’s hand, and
Enhanced gearing and intuitive wheel design that enables seamless deployment and retraction of the microcatheter.

“The OMNI Surgical System has been revolutionary for my practice because of its effectiveness and ability to offer titratable therapy to a wide range of patients with glaucoma,” said Blake K. Williamson MD, MPH, MS, refractive surgeon and MIGS expert at Williamson Eye in Baton Rouge, La. “These changes will improve the functionality and intuitive use of the OMNI System, making it even more comfortable and efficient to perform both viscodilations and trabeculotomies.”

Initial published results from early use of the OMNI Surgical System show meaningful reductions in intraocular pressure (IOP) and medication use.1 Several large-scale, multi-center retrospective and prospective MIGS clinical studies further evaluating the OMNI Surgical System are underway and in their advanced stages.

About OMNI® Surgical System
The OMNI Surgical System is a manually operated device for delivery of small amounts of viscoelastic fluid, for example Healon® or HealonGV® from Abbott Medical Optics (AMO), Amvisc® from Bausch & Lomb, or PROVISC® from Alcon, during ophthalmic surgery. It is also indicated to cut trabecular meshwork tissue during trabeculotomy procedures.

The OMNI System should not be used in cases where there is insufficient visualization of the anterior chamber. The following conditions may prohibit sufficient visualization required for safe and successful cannula and microcatheter placement: corneal edema, corneal haze, corneal opacity, or any other conditions that may inhibit surgeon view.

The OMNI Surgical System is a tool, not a treatment, and is indicated for use as specified above; it is not specifically cleared by the FDA to lower intraocular pressure in patients with open angle glaucoma.

About Sight Sciences
Founded in 2011, Sight Sciences has developed, and is now commercial with intelligently designed and engineered products that target the underlying causes of the world’s most prevalent eye diseases. The company’s surgical glaucoma product portfolio features the OMNI® Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target of all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm’s canal, and collector channels) with a single device and single corneal incision.

Activ Surgical, a pioneering digital surgery company focused on improving surgical efficiency, accuracy, patient outcomes and accessibility, announced its ActivEdge platform. ActivEdge, an artificial intelligence (AI) and machine-learning (ML) platform, is designed to provide critical real-time intelligence and visualization to improve patient outcomes, avoid preventable surgical errors and complications, and provide significant overall savings to healthcare systems. The platform and its associated products will be initially available in the U.S. market, with plans to commercialize globally in 2021.

The future of surgery is collaborative, with human judgment and wisdom augmented by robotics precision,” said Todd Usen, CEO, Activ Surgical. “With nearly 400,000 deaths in the U.S. every year due to avoidable medical errors, our surgical intelligence platform is designed to dramatically improve outcomes, safety and accessibility by arming surgeons with real-time information to make better informed decisions. We look forward to empowering global access to best-in-class surgery, regardless of location – saving millions of lives in the process.”

Preventable medical errors are currently the third leading cause of death, after heart attacks and cancer. Surgical errors account for 26% of these errors and are estimated to cost more than $36 billion in the U.S. Activ Surgical will initially focus on the 2.2 million most common laparoscopic procedures, including Cholecystectomy, Colectomy, Hysterectomy and Gastrectomy, where blood flow and critical structure identification are crucial to optimal outcomes.

“Innovation in the surgical vision category is long overdue; the most commonly employed surgical imaging process, ICG, uses fluorescent dye invented more than 70 years ago and does not offer real-time, objective physiologic information to surgeons when they critically need it during procedures,” said Dr. Peter Kim, co-founder and chief science officer, Activ Surgical. “Activ Surgical is designed to empower surgeons to make better informed decisions by offering real-time intelligence and visualization to dramatically reduce medical complications and surgical errors.”

“The next frontier in surgery is advanced imaging, led by innovation from companies like Activ Surgical, to enable intraoperative imaging and image overlays, guided by machine learning,” said Dr. Vipul (Vip) Patel, Medical Director of the Global Robotics Institute at Advent Health Celebration and Medical Director of the Advent Health Cancer Institute Urologic Oncology Program and Activ Survical Advisory Board member. “The potential for Activ Surgical to use AI and machine learning to inform robotics-assisted surgery – bringing together the best of human judgment and wisdom augmented by robotics precision – is a game changer in helping the surgical community achieve better outcomes.”

According to Dr. Steven D Schwaitzberg, Professor and Chairman of the Department of Surgery at University at Buffalo and Activ Surgical Advisory Board member, “As a surgeon, I rely heavily on surgical imaging to make informed decisions regarding procedures. Now that the majority of imaging systems have achieved optimal optical resolution, the next phase of innovation will be driven by companies like Activ Surgical who are developing new value-added features, including the visualization of tissue perfusion.”

Activ Surgical’s product portfolio, built on its ActiveEdge platform, includes hardware agnostic imaging software and computer-driven guidance systems, both for scopes and robots, to improve situational awareness and real-time imaging during surgical procedures and enable safe tissue access.

ActivSight, the first product based on the company’s platform, works dynamically and seamlessly with any installed visualization system to provide real-time intraoperative visual data and images not currently available to surgeons through existing technologies. The imaging module is an easy-to-adapt, connected platform that seamlessly attaches to today’s laparoscopic and arthroscopic systems so outcomes can be improved immediately, providing real-time, on demand insights, integrated into standard monitors. With ActivSight, surgical systems – from scopes to robots – can visualize blood flow in real-time with no workflow impact, unlike ICG, which does not offer real-time information to surgeons. ActivSight is expected to be cleared by the FDA in 2020. To date, eight major hospital networks across the U.S. have been established as pilot sites.

ActivInsight, the company’s second product, will transform massive amounts of data gathered intraoperatively to help characterize tissue and critical structures, providing surgeons with augmented visuals and real-time guidance. The AI and ML-based product will be designed for continuous improvement and will be underpinned by one of the industry’s largest annotated data sets to be developed by Activ Surgical over the next 12 months. ActivInsight is expected to be available within the next two years.

Additional robotics-assisted surgery offerings, ActivAssist and ActivPilot, are also in active development. ActivAssist will use ML based on the ActivInsight data set to optimally position scopes, allowing surgeons to perform at the highest level. ActivPilot will perform autonomous procedures with a surgeon in the loop to consistently achieve best-possible outcomes. Anticipated release dates for these early stage offerings are not being shared at this time.

About Activ Surgical
Founded in 2017, Activ Surgical is a first-of-its-kind digital surgery company focused on improving surgical efficiency, accuracy, patient outcomes and accessibility for both endoscopic and robotically-assisted procedures. The company completed the world’s first autonomous robotic surgery of soft tissue, and is building hardware-agnostic surgical software that allows minimally invasive surgical systems to autonomously collaborate with surgeons. Activ Surgical’s patent-protected surgical software platform reduces unintended and preventable surgical complications by using artificial intelligence, computer vision, machine learning and analytics to enhance a surgeon’s intra-operative decision making. Activ Surgical is privately held, and backed by leading global venture capital firms including DNS Capital, GreatPoint Ventures (GPV), Tao Capital Partners, SONY Innovation Fund, Rising Tide Financial, WS Investment Company and Mintz.

XSOLIS, the company channeling health care data into predictive intelligence and action, announced that it has partnered with Hillcrest HealthCare System (HHS) for technology-driven utilization review and payer connectivity.

Hillcrest HealthCare System will utilize CORTEX, XSOLIS’ technology platform, to increase efficiency and maintain clinical integrity during medical necessity reviews through real-time predictive analytics, and also offer payer partners the opportunity to review and automate case reviews through CORTEX.

“The importance of efficiency and payer connections have been made even more clear by this pandemic,” said Jeremy Gray, Director of Managed Care for HHS. “Our partnership with XSOLIS will allow us to leverage technology and innovation to better care for our patients, better collaborate with our partners, and increase our impact on our community.”

“To paraphrase from our friend Rikki Moye, VP of Case Management at HHS, we are committed to helping HHS bring innovative, non-traditional processes to bear in building a ‘right care’ case management model,” said Joan Butters, CEO and cofounder of XSOLIS. “With the exceptional team at HHS dedicated to breaking down silos between provider and payer, we will help them create a new foundation for utilization management.”

About Hillcrest HealthCare System

In 1918, Hillcrest opened its doors to provide hope, health and healing to our community in a small hospital located in the heart of the city. Today, Hillcrest HealthCare System (HHS) is comprised of eight hospitals including Hillcrest Medical Center, Hillcrest Hospital South and Tulsa Spine & Specialty Hospital in Tulsa, as well as five regional hospitals, Hillcrest Hospital Claremore, Hillcrest Hospital Cushing, Hillcrest Hospital Henryetta, Hillcrest Hospital Pryor and Bailey Medical Center in Owasso. Hillcrest HealthCare System also provides comprehensive primary and specialty care services through Utica Park Clinic and Oklahoma Heart Institute.

About XSOLIS

XSOLIS is a healthcare technology firm focused on improving healthcare operations through cognitive computing. Partnering with some of the most forward-thinking healthcare organizations across the nation, XSOLIS transforms the utilization management process between payers and providers; CORTEX, XSOLIS’ technology platform, forms a data-driven framework for neutral, holistic determinations of medical necessity.